초록 ▼

A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magne

A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period of time that is less than 60 minutes.

대표청구항 ▼

1. A dry powder inhaler device comprising a stable dry powder formulation for inhalation, the powder comprising active particles and carrier particles for supporting the active particles, the formulation further comprising magnesium stearate in an amount of at least 0.5% by weight of the formulation

1. A dry powder inhaler device comprising a stable dry powder formulation for inhalation, the powder comprising active particles and carrier particles for supporting the active particles, the formulation further comprising magnesium stearate in an amount of at least 0.5% by weight of the formulation, wherein the particles of magnesium stearate are disposed on the surface of the carrier particles to provide a surface coverage of less than 5% on the carrier particles. 2. The dry powder inhaler device of claim 1, wherein the magnesium stearate is present in an amount of from 0.5 to 2% by weight. 3. The dry powder inhaler device of claim 1, wherein the magnesium stearate is present in an amount of from 0.6 to 1% by weight. 4. The dry powder inhaler device of claim 1, wherein the active particles comprise an active substance selected from the group consisting of beta-mimetics, anticholinergics, corticosteroids, leukotriene antagonists, phosphodiesterase inhibitors, PAF-inhibitors, potassium channel openers, analgesics, potency agents, macromolecules, pharmaceutically acceptable salts thereof and mixtures thereof. 5. The dry powder inhaler device of claim 1, wherein the carrier particles comprise a carrier material selected from monosaccharides, disaccharides, sugar alcohols, polylactic acid, or mixtures thereof. 6. The dry powder inhaler device of claim 5, wherein the carrier material is lactose mono-hydrate. 7. The dry powder inhaler device of claim 4, wherein the beta-mimetic is selected from the group consisting of Levalbuterol, Terbutalin, Reproterol, Salbutamol, Salmeterol, Formoterol, Fenoterol, Clenbuterol, Bambuterol, Tulobuterol, Broxaterol, Epinephrin, Isoprenaline and Hexoprenaline. 8. The dry powder inhaler device of claim 4, wherein the anticholinergic is selected from the group consisting of Tiotropium, Ipratropium, Oxitropium and Glycopyrronium. 9. The dry powder inhaler device of claim 4, wherein the corticosteroid is selected from the group consisting of Butixocart, Rofleponide, Budesonide, Ciclosenide, Mometasone, Fluticasone, Beclomethasone, Loteprednol and Triamcinolone. 10. The dry powder inhaler device of claim 4, wherein the leukotriene antagonist is selected from the group consisting of Andolast, Iralukast, Pranlukast, Imitrodast, Seratrodast, Zileuton, Zafirlukast and Montelukast. 11. The dry powder inhaler device of claim 4, wherein the phosphodiesterase-inhibitor is selected from Filaminast or Piclamilast. 12. The dry powder inhaler device of claim 4, wherein the PAF-inhibitor is selected from the group consisting of Apafant, Forapafant and Israpafant. 13. The dry powder inhaler device of claim 4, wherein the potassium channel opener is selected from Amiloride or Furosemide. 14. The dry powder inhaler device of claim 4, wherein the analgesic is selected from the group consisting of Morphine, Fentanyl, Pentazocine, Buprenorphine, Pethidine, Tilidine, Methadone and Heroin. 15. The dry powder inhaler device of claim 4, wherein the potency agent is selected from the group consisting of Sildenafil, Alprostadil and Phentolamine. 16. The dry powder inhaler device of claim 4, wherein the macromolecule is selected from the group consisting of proteins, peptides, oligopeptides, polypeptides, polyamino acids, nucleic acids, polynucleotides, oligo-nucleotides and high molecular weight polysaccharides. 17. The dry powder inhaler device of claim 5, wherein the monosaccharide or disaccharide is selected from the group consisting of glucose, lactose, lactose monohydrate, sucrose, trehalose and mixtures thereof. 18. The dry powder inhaler device of claim 5, wherein the sugar alcohol is selected from mannitol, xylitol, or a mixture thereof.